Ultragenyx's earnings call showcased significant achievements, including program approvals, Breakthrough Therapy designation, and strong revenue growth. However, challenges such as delays in BLA submissions and financial losses were also highlighted.

Company Guidance

During the Ultragenyx Second Quarter 2025 Financial Results Conference Call, the company provided detailed guidance on its financial and clinical progress. Total revenue for the first half of 2025 reached $306 million, a 20% increase from the previous year, with Crysvita contributing $120 million in the second quarter. The company's revenue guidance for 2025 was reaffirmed at $640 million to $670 million, representing a 14% to 20% growth over 2024. Operational expenses for the quarter were $274 million, leading to a net loss of $115 million. Ultragenyx reported having $539 million in cash, cash equivalents, and marketable securities as of June 30, 2025. Significant clinical milestones include ongoing Phase III trials for UX143 and GTX-102, with top-line data for UX143 expected around the end of the year, and the GTX-102 Phase III Aspire study anticipated to read out in the second half of 2026. The company aims for GAAP profitability by 2027, focusing on growing revenues and diligently managing expenses.

15-Year Anniversary and Program Approvals

Ultragenyx marked its 15-year anniversary, having taken 4 programs through approval in multiple regions and added a fifth for commercialization outside the U.S.

UX143 Progress for Osteogenesis Imperfecta

The UX143 program continues with positive safety profiles and expectations for successful Phase III study outcomes.

GTX-102 Receives Breakthrough Therapy Designation

GTX-102 for Angelman syndrome was granted Breakthrough Therapy designation by the FDA based on Phase I/II data showing developmental gains.

Strong Revenue Growth

Total revenue for the first half of 2025 grew by 20% compared to 2024, driven by double-digit growth across multiple product lines.

Successful Commercialization Efforts

The commercial team successfully launched and grew products like Crysvita, Dojolvi, and Evkeeza, with Crysvita seeing new patient starts and geographic expansion.

Ultragenyx Pharmaceutical (RARE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RARE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	-1.23 / -	-1.4	―	―	―
Aug 05, 2025	2025 (Q2)	-1.30 / -1.17	-1.52	23.03% (+0.35)
May 06, 2025	2025 (Q1)	-1.60 / -1.57	-2.03	22.66% (+0.46)
Feb 13, 2025	2024 (Q4)	-1.31 / -1.39	-1.52	8.55% (+0.13)
Nov 05, 2024	2024 (Q3)	-1.48 / -1.40	-2.23	37.22% (+0.83)
Aug 01, 2024	2024 (Q2)	-1.66 / -1.52	-2.25	32.44% (+0.73)
May 02, 2024	2024 (Q1)	-1.75 / -2.03	-2.33	12.88% (+0.30)
Feb 15, 2024	2023 (Q4)	-1.71 / -1.52	-2.16	29.63% (+0.64)
Nov 02, 2023	2023 (Q3)	-2.08 / -2.23	-3.5	36.29% (+1.27)
Aug 03, 2023	2023 (Q2)	-2.09 / -2.25	-2.26	0.44% (<+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RARE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$28.92	$28.05	-3.01%
May 06, 2025	$35.06	$33.42	-4.68%
Feb 13, 2025	$43.52	$42.49	-2.37%
Nov 05, 2024	$52.18	$50.52	-3.18%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Ultragenyx Pharmaceutical (RARE) report earnings?

Ultragenyx Pharmaceutical (RARE) is schdueled to report earning on Nov 04, 2025, TBA (Confirmed).

What is Ultragenyx Pharmaceutical (RARE) earnings time?

Ultragenyx Pharmaceutical (RARE) earnings time is at Nov 04, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RARE EPS forecast?

RARE EPS forecast for the fiscal quarter 2025 (Q3) is -1.23.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing